Literature DB >> 20054285

Sequential therapy for Helicobacter pylori eradication: a critical review.

Javier P Gisbert1, Xavier Calvet, Anthony O'Connor, Francis Mégraud, Colm A O'Morain.   

Abstract

BACKGROUND: Alternative treatment regimens for standard triple therapy are urgently needed. AIM: To critically review the evidence on the role of "sequential" regimen for the treatment of Helicobacter pylori infection.
METHODS: Bibliographical searches were performed in MEDLINE and international congresses.
RESULTS: Several pooled-data analyses and meta-analyses have demonstrated that sequential regimen is more effective than standard triple therapy. Sequential therapy is not affected by bacterial (CagA status, infection density) and host factors (underlying disease, smoking). Clarithromycin resistance seems to be the only factor reducing their efficacy. However, even in these patients, an acceptable >75% eradication rate can be achieved. Unfortunately, almost all the studies have been performed in Italy. Whether it is necessary to provide the drugs sequentially or if the 4 components of sequential therapy can be given concurrently is unclear. Nonbismuth quadruple therapy seems to be an effective and safe alternative to triple therapy and is less complex than sequential therapy.
CONCLUSIONS: Sequential therapy is a novel promising treatment approach that deserves consideration as a treatment strategy for H. pylori infection. However, further robust assessment across a much broader range of patients is required before sequential therapy could supplant existing treatment regimens and be generally recommended in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20054285     DOI: 10.1097/MCG.0b013e3181c8a1a3

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  64 in total

1.  First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective.

Authors:  György-Miklós Buzás
Journal:  World J Gastroenterol       Date:  2010-08-21       Impact factor: 5.742

2.  Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial.

Authors:  Nabil Ben Chaabane; Hamad Saadoon Al-Adhba
Journal:  Indian J Gastroenterol       Date:  2015-02-28

3.  Helicobacter pylori eradication: A new, single-capsule bismuth-containing quadruple therapy.

Authors:  Javier P Gisbert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06       Impact factor: 46.802

4.  Empiric therapies for Helicobacter pylori infections.

Authors:  David Y Graham; Lori A Fischbach
Journal:  CMAJ       Date:  2011-02-22       Impact factor: 8.262

5.  The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy.

Authors:  Francis Mégraud
Journal:  Therap Adv Gastroenterol       Date:  2012-03       Impact factor: 4.409

Review 6.  Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance.

Authors:  Javier Molina-Infante; Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

7.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

Review 8.  Helicobacter pylori: future perspectives in therapy reflecting three decades of experience.

Authors:  Tajana Filipec Kanizaj; Nino Kunac
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 9.  Eradication of Helicobacter pylori infection: which regimen first?

Authors:  Alessandro Federico; Antonietta Gerarda Gravina; Agnese Miranda; Carmela Loguercio; Marco Romano
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

10.  Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials.

Authors:  Lien-Chieh Lin; Tzu-Herng Hsu; Kuang-Wei Huang; Ka-Wai Tam
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.